Assistant Professor of Medicine, UCSF
Cancer Center Program Membership
- Research
- Training
- Awards
- Publications
Research Summary
Dr. Michael Li is a transplant hepatologist and gastroenterologist who specializes in caring for patients with cirrhosis, autoimmune liver disease, and liver cancer.
Dr. Li’s research focuses on the relationship between the immune system and liver disease. This includes autoimmune diseases like primary sclerosing cholangitis as well as the use of immunotherapy to treat liver cancer. He seeks to perform meaningful clinical and translational research to achieve a better understanding of immune-mediated liver diseases.
Dr. Li earned his medical degree at the Icahn School of Medicine at Mount Sinai and completed a residency in internal medicine at the Mount Sinai Hospital. He completed a fellowship in gastroenterology at Brigham and Women's Hospital, during which he also earned his MPH degree from the Harvard TH Chan School of Public Health. He then completed a fellowship in transplant hepatology at UCSF before becoming a faculty member in the UCSF Division of Gastroenterology and Hepatology.
Research Funding
July 1, 2023 - June 30, 2026 - Predictors and biomarkers of immunotherapy response and toxicity in hepatocellular carcinoma , Principal Investigator . Sponsor: The American College of Gastroenterology, Sponsor Award ID: Junior Faculty Development Award
July 1, 2023 - June 30, 2025 - Novel proteome-wide autoantibody discovery in primary sclerosing cholangitis , Principal Investigator . Sponsor: PSC Partners, Sponsor Award ID: Young Investigator Award
Education
Fellowship, 2022 - Transplant Hepatology, UCSF
Fellowship, 2021 - Gastroenterology, Brigham and Women's Hospital
MPH, 2021 - Clinical Effectiveness, Harvard TH Chan School of Public Health
Residency, 2018 - Internal Medicine, The Mount Sinai Hospital
MD, 2015 - , Icahn School of Medicine at Mount Sinai
BS, 2010 - Biology, Brown University
Honors & Awards
- Pilot Research Award, American Gastroenterological Association, 2023
- Pilot/Feasibility Award, UCSF Liver Center, 2023
- Clinical Research Pilot Study Award, American College of Gastroenterology, 2021
- AASLD Foundation Fellow Abstract Award, Digestive Disease Week, 2021
- Best of the Liver Meeting, Basic and Translational Research, AASLD, 2020
- Honors in Research, Mount Sinai Internal Medicine, 2018
- Presidential Poster of Distinction, AASLD, 2014
- Howard Hughes Medical Research Fellowship, Howard Hughes Medical Institute, 2013-2014
- Mount Sinai Research Scholars Program, Icahn School of Medicine at Mount Sinai, 2011
- Undergraduate Teaching and Research Award, Brown University, 2008
- Summer Medical and Research Training Program Fellowship, Baylor College of Medicine, 2007
Selected Publications
- Li M, Wong D, Sack JS, Vogel AS, Hodi FS, Fong L, Lai JC, Grover S, Zucker SD. Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis. J Natl Compr Canc Netw. 2023 06; 21(6):617-626.e3.View on PubMed
- Zahir A, Li M, Gill RM, Brandman D. Diagnosis and Management of Drug-Induced Liver Injury After the Use of Polygonum multiflorum. ACG Case Rep J. 2022 Oct; 9(10):e00884.View on PubMed
- Li M, Wong D, Vogel AS, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022 03; 75(3):531-540.View on PubMed
- Li M, Sack JS, Bell P, Rahma OE, Srivastava A, Grover S, Zucker SD. Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer. JAMA Oncol. 2021 11 01; 7(11):1711-1714.View on PubMed
- Bazarbashi AN, Li M, Ryou M. Letter to the Editor: Endoscopic Ultrasound-Guided Coil Therapy for Secondary Prevention After Gastric Variceal Bleeding: A Promising Alternative. Hepatology. 2021 11; 74(5):2914.View on PubMed
- Sack JS, Li M, Zucker SD. Bleeding Outcomes Following Transesophageal Echocardiography in Patients With Cirrhosis and Esophageal Varices. Hepatol Commun. 2021 02; 5(2):283-292.View on PubMed
- Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen VL, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin KD, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch AD, Viveiros K, Chan W, Chascsa DM, Kwo P, Dhanasekaran R. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clin Gastroenterol Hepatol. 2021 Jul; 19(7):1469-1479.e19.View on PubMed
- Li M, Chan WW, Zucker SD. Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV. J Am Heart Assoc. 2020 10 20; 9(19):e016310.View on PubMed
- Li M, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer. 2020 12 01; 126(23):5088-5097.View on PubMed
- Li M, Pathak RR, Lopez-Rivera E, Friedman SL, Aguirre-Ghiso JA, Sikora AG. The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. J Vis Exp. 2015 Oct 09; (104).View on PubMed
Go to UCSF Profiles, powered by CTSI
